Comparison of the safety of tilboptin and semaglutide

Tirzepatide and semaglutide are both GLP-1 receptor agonists, and common side effects include gastrointestinal discomfort such as nausea, vomiting, diarrhea, and constipation. These side effects are mainly related to the mechanism of action of GLP-1 and may affect the central nervous system. However, as a dual agonist, tirzepatide also involves activation of GIP (gastric inhibitory peptide) receptors. GIP not only reduces appetite, but may also alleviate some of the side effects caused by GLP-1, thereby improving patient tolerance.

Research data shows that about 80% of users of tirzepatide report at least one side effect, with the majority being gastrointestinal discomfort (such as nausea, diarrhea, constipation, or vomiting), which is also a common side effect of semaglutide. In clinical trials, 33% of patients taking the highest dose of tirzepatide reported nausea, while the proportion for semaglutide was 44%. In addition, 23% of patients with telmisartan experienced diarrhea, while the proportion with semaglutide was 31%.

Gastroenterology expert Christopher McGowan stated that compared to semaglutide, the dual effects of tilboptin GLP-1 and GIP may lead to fewer and milder symptoms. The side effects are similar, mainly gastrointestinal side effects, with symptoms often mild to moderate and improving over time. The overall incidence of side effects is lower, but his patients have reported better tolerance after transitioning from semaglutide to tirzepatide.

In response to the growing demand for tirzepatide, Lilly announced its largest production capacity investment in its 150 year history, adding $5.3 billion to increase the total investment to $9 billion for expanding tirzepatide production. Since 2022, Lilly's global production capacity of incretin injection drugs in the treatment of type 2 diabetes and obesity has doubled. Despite facing supply shortages in the past, the issue of tilboptide has now been alleviated.

The approval of tirzepatide and semaglutide provides more options for patients seeking weight management. Although the side effects of the two are similar, tiltrotide may provide better tolerance through a dual activation mechanism. At the same time, the good therapeutic effect and low price of tirzepatide make it an ideal choice for many patients.